{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T08:08:58Z","timestamp":1782461338922,"version":"3.54.5"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"24","license":[{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction:<\/jats:title>\n            <jats:p>Bladder cancer is the tenth most common cancer worldwide, with Europe having the highest incidence rates. Regarding the treatment of metastatic disease, first-line treatment for fit patients is cisplatin-containing combination chemotherapy. However, a significant percentage of patients are ineligible for platinum-based chemotherapy, or progress under these regimens. Recently, immune checkpoint blockade has become a treatment option for this group of patients. In this report, we present the case of a male patient diagnosed with metastatic bladder cancer who did not tolerate cisplatin-containing chemotherapy and achieved complete response after treatment with pembrolizumab.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 58 years-old Caucasian man with a medical history of high-grade urothelial carcinoma pT3bN0R0 under a watchful waiting strategy for 6 months presented to the Medical Oncology appointment with two axillary and cervical adenopathies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis:<\/jats:title>\n            <jats:p>Cervicothoracoabdominal computed tomography confirmed the presence of two large necrotic lymphadenopathies in the cervical and axillary lymphatic chains, and bone scintigraphy revealed dorsal (D11) and lumbar (L5) metastatic lesions. Ultrasonography-guided biopsy of the axillary nodule revealed the presence of metastatic tissue of primary urothelial origin.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>The patient was initiated on a palliative chemotherapy regimen of carboplatin area under the curve 5 plus gemcitabine (1000\u200amg\/m<jats:sup>2<\/jats:sup>). During the first cycle of chemotherapy, acute kidney failure akin 2 developed due to nonobstructive toxic acute tubular necrosis with progressive deterioration of kidney function. Therefore, palliative chemotherapy with carboplatin plus gemcitabine was changed to 200\u200amg of pembrolizumab every 21 days.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>Overal survival of 57 months with an immune complete response according to the immune Response Evaluation Criteria in Solid Tumours criteria and an excellent quality of life.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>This case illustrates that second-line therapy with ICIs (pembrolizumab or atezolizumab) has favourable results in achieving an immune complete response after intolerance to cisplatin-based regimens. ICIs provide durable responses that improve overall survival and quality of life.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000028940","type":"journal-article","created":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T13:04:16Z","timestamp":1655471056000},"page":"e28940","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Complete and long-lasting response to immunotherapy"],"prefix":"10.1097","volume":"101","author":[{"given":"Diogo J.","family":"Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Mesquita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,6,17]]},"reference":[{"key":"R1-20250612","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","article-title":"Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Powles","year":"2014","journal-title":"Annals of Oncology"},{"key":"R2-20250612","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.eururo.2009.01.002","article-title":"The updated EAU guidelines on muscle-invasive and metastatic bladder cancer","volume":"55","author":"Stenzl","year":"2009","journal-title":"Eur Urol"},{"key":"R3-20250612","doi-asserted-by":"crossref","first-page":"1758835918788310","DOI":"10.1177\/1758835918788310","article-title":"Approved checkpoint inhibitors in bladder cancer: which drug should be used when?","volume":"10","author":"Ghatalia","year":"2018","journal-title":"Ther Adv Med Oncol"},{"key":"R4-20250612","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ctrv.2019.04.002","article-title":"Management of metastatic bladder cancer","volume":"76","author":"Nadal","journal-title":"Cancer Treat Rev Internet"},{"key":"R5-20250612","first-page":"1921","article-title":"Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial","volume":"18","author":"Kaufman","year":"2019","journal-title":"Cancer"},{"key":"R6-20250612","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1200\/JCO.2011.37.3571","article-title":"Randomized phase II\/III trial assessing Gemcitabine\/Carboplatin and Methotrexate\/Carboplatin\/Vinblastine in Patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986","volume":"30","author":"Santis","year":"2012","journal-title":"J Clin Oncol"},{"key":"R7-20250612","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","article-title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncol Internet"},{"key":"R8-20250612","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"R9-20250612","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S1470-2045(17)30007-4","article-title":"Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study","volume":"18","author":"Plimack","year":"2017","journal-title":"Lancet Oncol Internet"},{"key":"R10-20250612","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1093\/annonc\/mdz127","article-title":"Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: Results of >2 years of follow-up","volume":"30","author":"Fradet","year":"2019","journal-title":"Ann Oncol"},{"key":"R11-20250612","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/annonc\/mdz003","article-title":"Novel patterns of response under immunotherapy","volume":"30","author":"Borcoman","year":"2019","journal-title":"Ann Oncol"},{"key":"R12-20250612","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1200\/EDBK_200643","article-title":"Patterns of Response and Progression to Immunotherapy","volume":"38","author":"Borcoman","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"R13-20250612","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol Internet"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000028940","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T19:00:22Z","timestamp":1749754822000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000028940"}},"subtitle":["A case report of urothelial cancer"],"short-title":[],"issued":{"date-parts":[[2022,6,17]]},"references-count":13,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000028940","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,17]]},"assertion":[{"value":"2022-01-20","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-09","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}